Cart
sales@molnova.com
GSK256073
CAS No. 862892-90-8
GSK256073( —— )
Catalog No. M24859 CAS No. 862892-90-8
GSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 169 | In Stock |
|
| 2MG | 93 | In Stock |
|
| 5MG | 155 | In Stock |
|
| 10MG | 250 | In Stock |
|
| 25MG | 440 | In Stock |
|
| 50MG | 634 | In Stock |
|
| 100MG | 901 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameGSK256073
-
NoteResearch use only, not for human use.
-
Brief DescriptionGSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist.
-
DescriptionGSK256073 is an orally active GPR109A agonist. GSK256073 also is a long-lasting and non-flushing HCA2 (hydroxy-carboxylic acid receptor 2) full agonist (pEC50: 7.5). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis.
-
In Vitro——
-
In VivoAnimal Model:SD ratDosage:1, 30 and 100 mg/kg Administration:Oral adminstration Result:Inhibited NEFA expression as a dose-dependent manner. Animal Model:Guinea pigs Dosage:10 mg/kg Administration: Intravenous?injection Result:Had the antilipolytic and flushing effects as a HCA2 agonist.
-
Synonyms——
-
PathwayCell Cycle/DNA Damage
-
TargetGPR
-
RecptorGPR109A|HCA2 (hydroxy-carboxylic acid receptor 2)
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number862892-90-8
-
Formula Weight256.69
-
Molecular FormulaC10H13ClN4O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:16.67 mg/mL?(64.94 mM;?Need ultrasonic)
-
SMILESCCCCCN1C2=C(C(=O)NC1=O)NC(=N2)Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dobbins RL, et al. GSK256073, a selective agonist of G-protein coupled receptor 109A (GPR109A) reduces serum glucose in subjects with type 2 diabetes mellitus.Diabetes Obes Metab.?2013 Nov;15(11):1013-21.
molnova catalog
related products
-
ZK 756326
ZK 756326 is a selective, non-peptide CCR8 chemokine receptor agonist (IC50: 1.8 μM, in human; 2.6?μM, in mouse).
-
APD 668
APD668 is a potent GPR119 agonist with EC50 of 2.7 nM and 33 nM for hGPR119 and ratGPR119 respectively.
-
Ogremorphin
Ogremorphin (GPR68-IN-1) is a potent inhibitor of GPR68 with an EC50 of 170 nM, used in the study of autoimmune chronic inflammatory diseases .
